{"prompt": "['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', 'Day', 'D29', 'Time (hour/minute)', 'At arrival', 'OH Study', '1H', '2H', '3H before', 'Additional hours', 'at the site', 'drug intake', 'leaving', \"at Investigator's\", 'the site', 'discretion', 'Body weight', 'X', 'Vital signs 12 lead-ECGe', 'X', 'Hematology, biochemistry, urinalysis,', 'X', 'Renal function (blood creatinine and cystatin C)', 'X', 'Adverse event collection', 'Pharmacokinetics', 'SAR407899 plasma samples', 'X', 'DME = drug metabolizing enzymes; ECG = electrocardiogram; IMP = investigational medicinal product.', 'Note: when several items take place at the same time, the following order should be respected: questionnaires, ECG, vital signs, blood sampling, drug administration, pharmacodynamics, meal.', 'In order to respect exact timing of pharmacokinetic samples, the other measures will be done ahead of the scheduled time.', 'a', 'Time (hour/minute) is expressed in reference to the last administration of SAR407899 (TOH).', 'b Restriction rules for CFR assessed by vasodilator stress PET scan (detailed in Section 10.1.4) to follow.', 'C On Day 29 or up to 2 days after (at the latest if not otherwise possible) CFR assessed by vasodilator stress PET scan should be performed approximately 1 to 2 hours after morning IMP intake.', 'd Refer to Safety section for detailed safety investigations.', 'e Vital signs should be performed by the investigator or designee. Continuous monitoring of heart rate, BP and 12-lead ECG should be performed throughout the stressor infusion.', 'f Vital signs: BP & Heart rate measurements including search of hypotension (orthostatic or not).', 'g', 'IMP administration should be continued until the day of the CFR assessment by vasodilator PET scan.', 'h Only for PET scan.', 'i', \"Based on Investigator's judgement, the patient may be discharged later for safety reasons.\", 'j', 'To be performed 1 to 3 hours after dosing.', 'Property of the Sanofi Group - strictly confidential', 'Page 21', '(electronic 4.0)']['Amended Clinical Trial Protocol NO 03', '18-Apr-2018', 'ACT14656', 'Version number: 1', '2', 'TABLE OF CONTENTS', '1', 'FLOW CHARTS', '9', '1.1', 'GRAPHICAL STUDY DESIGN', '9', '1.2', 'POTENTIAL TITRATION SCHEDULES & DECISION RULES STUDY', '10', '1.3', 'STUDY FLOW CHARTS', '11', '1.3.1', 'Study flow chart for patients with previous coronary artery angiography or CCTA within 24', 'months prior to screening', '11', '1.3.2', 'Study flow chart for patients diagnosed with MVA and stable angina without previous PCI', 'and with previous coronary artery angiography or CCTA between 24 months and 5 years', 'prior to screening, who need CCTA during screening period', '13', '1.4', 'DAY 1 FLOW CHART', '16', '1.4.1', 'Flow chart with PET scan on Day 1 (not applicable for patients diagnosed with MVA and', 'stable angina without previous PCI and with previous coronary artery angiography or', 'CCTA between 24 months and 5 years prior to screening, who need CCTA during', 'screening period)', '16', '1.4.2', 'Flow chart with PET scan prior to Day 1', '18', '1.5', 'DAY 29 FLOW CHART SUGGESTED TIME FRAME (CAN BE ADAPTED BY SITE)', '20', '2', 'TABLE OF CONTENTS', '22', '2.1', 'LIST OF TABLES', '27', '2.2', 'LIST OF FIGURES', '27', '3', 'LIST OF ABBREVIATIONS', '28', '4', 'INTRODUCTION AND RATIONALE', '30', '4.1', 'GENERAL BACKGROUND', '30', '4.1.1', 'Background on patient population', '30', '4.1.1.1', 'Patients with persistent angina despite angiographically successful PCI', '30', '4.1.1.2', 'Patients with microvascular angina (MVA)', '30', '4.1.1.3', 'Pathophysiology and purported beneficial mechanism of Rho-Kinase inhibition:', '30', '4.2', 'BACKGROUND ON SAR407899', '32', '4.3', 'RATIONALE FOR THE STUDY', '32', '4.4', 'DESIGN RATIONALE AND RISK ASSESSMENT', '32', '5', 'STUDY OBJECTIVES', '36', '5.1', 'PRIMARY', '36', 'Property of the Sanofi Group - strictly confidential', 'Page 22', '(electronic 4.0)']\n\n###\n\n", "completion": "END"}